EMERGING GENETIC BIOMARKERS FOR ICC DIAGNOSIS AND PROGNOSIS

Identifying Potential Biomarkers for Early Detection

Identifying new biomarkers for the early diagnosis of iCCA is essential for enhancing patient outcomes, given that the illness is frequently detected at advanced stages [76]. Biomarkers may be identified in blood, bile, or tissue samples, and can encompass genetic, epigenetic, proteomic, and metabolomic modifications. Prevalent genetic alterations, including IDH1/2, FGFR2 fusions, and BAP1 mutations, have been recognized as prospective biomarkers [77]. Furthermore, increased serum markers, such as CA19-9 and CEA, are frequently correlated with iCCA; however, they lack specificity. Epigenetic modifications, including DNA methylation patterns in tumor suppressor genes, such as RASSF1A, and altered expression of microRNAs (e.g., miR-21), are under investigation as potential early diagnostic markers [78]. Proteomic analysis has revealed anomalous proteins associated with tumor proliferation and immune response. Liquid biopsies that examine circulating tumor DNA (ctDNA) and exosomes present promising non-invasive methods for early detection [79]. The integration of various biomarkers may improve diagnostic precision and enable earlier action.

Genetic Markers Associated with Prognosis and Survival Rates

Genetic indicators are crucial for predicting prognosis and survival rates in iCCA, providing insights into tumor dynamics and possible therapeutic responses. Mutations in genes, such as TP53 and KRAS, correlate with unfavorable prognosis, aggressive tumor proliferation, and reduced overall survival. TP53 mutations impair normal cell cycle regulation, resulting in unregulated proliferation, whereas KRAS mutations stimulate oncogenic signaling, facilitating tumor advancement and therapeutic resistance. In contrast, specific genetic modifications are associated with improved results. IDH1/2 mutations, found in a portion of iCCA patients, correlate with reduced tumor development and enhanced survival, perhaps attributable to the accessibility of targeted therapy, such as IDH inhibitors [80]. Likewise, FGFR2 fusions signify a more favorable prognosis, as they demonstrate a positive response to FGFR-targeted therapy. Additional indicators, including BAP1 mutations, are associated with chromatin remodeling abnormalities and exhibit variable prognostic significance contingent upon the tumor setting. Furthermore, ARID1A mutations, which play a role in chromatin remodeling, are linked to unfavorable consequences in certain instances [81]. The incorporation of genetic markers into clinical practice enhances prognostication and facilitates the customization of treatment methods, hence enhancing survival rates and quality of life for iCCA patients.

Liquid Biopsy and Circulating Tumor DNA (ctDNA) for Monitoring Disease Progression

Liquid biopsy and analysis of circulating tumor DNA (ctDNA) have emerged as potent, non-invasive methods for tracking disease development in iCCA. Liquid biopsies entail the examination of blood samples to identify circulating tumor DNA (ctDNA), which comprises fragmented DNA released into the circulation by apoptotic cancer cells [82]. This technique facilitates real-time evaluation of tumor dynamics, presenting numerous benefits compared to conventional tissue biopsies, including less patient risk, reproducibility, and the capacity to capture tumor heterogeneity. ctDNA analysis can identify particular genetic mutations linked to iCCA, including IDH1/2 mutations, FGFR2 fusions, and TP53 mutations, facilitating tailored treatment strategies [83]. Tracking ctDNA levels longitudinally aids in evaluating treatment efficacy, identifying minimum residual disease, and recognizing early indicators of recurrence or therapeutic resistance. A reduction in ctDNA levels may signify effective treatment, whereas an increase in ctDNA levels could indicate disease development prior to the manifestation of clinical signs. Additionally, ctDNA profiling can identify novel genetic variants that exhibit resistance to targeted medicines, facilitating prompt modifications in treatment approaches. With technological advancements, liquid biopsies are emerging as a crucial instrument for dynamic disease surveillance, providing optimism for enhanced outcomes via early intervention and tailored treatment in iCCA (Fig. 4) [84].